Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Long‐term treatment of breast‐cancer patients with the anti‐oestrogen tamoxifen has been found to be associated with reduced cardiovascular mortality. Plasma homocysteine is an independent risk factor for atherosclerotic disease, and its level is determined by folate and cobalamin status, and possibly also by oestrogen status. We measured the effect of tamoxifen on plasma homocysteine, serum cholesterol, serum cobalamin and serum and erythrocyte folate in 31 post‐menopausal women with breast cancer. The plasma homocysteine level was decreased by a mean value of 29.8% after 9–12 months and by 24.5% after 13–18 months of treatment. Tamoxifen suppressed serum cholesterol by mean values varying between 7.2% and 17.6% after 3 to 19 months of treatment. There was no correlation between changes in plasma homocysteine and serum cholesterol. These findings suggest that the homocysteine‐lowering effect of tamoxifen may contribute to the reduction of cardiovascular mortality observed in patients on adjuvant therapy with tamoxifen. © 1995 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
INCREASES IN STEROID BINDING GLOBULINS INDUCED BY TAMOXIFEN IN PATIENTS WITH CARCINOMA OF THE BREAST
SAKAI, F., CHEIX, F., CLAVEL, M., COLON, J., MAYER, M., POMMATAU, E., & SAEZ, S. (1978) · Journal of Endocrinology · doi:10.1677/joe.0.0760219 · Cited by 102
Cited by
Homocysteine and Cardiovascular Disease
Refsum, H., Ueland, P. M., Nygård, O., & Vollset, S. E. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.31 · Cited by 2,180
“Tamoxifen (96), estrogen replacement therapy (97), and aminothiol drugs (78, 79) may also reduce the plasma tHcy level.”
BackgroundSelf-citationFacts and recommendations about total homocysteine determinations: an expert opinion
Refsum, H., Smith, A. D., Ueland, P. M., Nexo, E., Clarke, R., McPartlin, J., Johnston, C., Engbaek, F., Schneede, J., McPartlin, C., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.021634 · Cited by 1,056
Self-citationTotal Plasma Homocysteine and Cardiovascular Risk Profile: The Hordaland Homocysteine Study
Nygård, O., Vollset, S. E., Refsum, H., Stensvold, I., Tverdal, A., Nordrehaug, J. E., Ueland, P. M., & Kvåle, G. (1995) · JAMA · doi:10.1001/jama.1995.03530190040032 · Cited by 1,042
Self-citationBasic Guide to the Mechanisms of Antiestrogen Action
Macgregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 694
Hogervorst, E., Williams, J., Budge, M., Riedel, W., & Jolles, J. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00410-3 · Cited by 439
Hyperhomocysteinemia, Atherosclerosis and Thrombosis
Cattaneo, M. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614438 · Cited by 362
Homocyst(e)ine and Risk of Cardiovascular Disease in the Multiple Risk Factor Intervention Trial
Evans, R. W., Shaten, B. J., Hempel, J. D., Cutler, J. A., & Kuller, L. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.10.1947 · Cited by 342
De Bree, A., Verschuren, W. M. M., Kromhout, D., Kluijtmans, L. A. J., & Blom, H. J. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.599 · Cited by 282
Total homocysteine and cardiovascular disease
Nygård, O., Vollset, S. E., Refsum, H., Brattström, L., & Ueland, P. M. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00512.x · Cited by 256
Self-citationA pharmacological review of selective oestrogen receptor modulators
Goldstein, S. R. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.212 · Cited by 205
Metadata
- Authors
- Anker, G., Lonning, P. E., Ueland, P. M., Refsum, H., & Lien, E. A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1995-01-27
- Volume
- 60
- Issue
- 3
- Pages
- 365-368
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2055900440
- Cited by
- 110
- References
- 1
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.